Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (41-50 of 868) with videos related to

Pageof 87
Sort By:
CA: a Cancer Journal for Clinicians|October 1, 2014
Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and backGiada Bianchi, Kenneth C Anderson
Haematologica|October 15, 2020
Multiple myeloma: the (r)evolution of current therapy and a glance into futureAnnamaria Gulla, Kenneth C Anderson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2006
Velcade and vitamin C: too much of a good thing?Laurence Catley, Kenneth C Anderson
Expert Opinion on Drug Safety|February 27, 2020
The safety of current and emerging therapies for multiple myelomaOmar Nadeem, Kenneth C Anderson
Oncology (Williston Park, N.Y.)|June 7, 2005
Treatment options for older myeloma patients. From the Multiple Myeloma Research FoundationKenneth C Anderson, Antonio Palumbo,
BMC Biology|November 1, 2011
Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130CasDharminder Chauhan, Kenneth C Anderson
International Journal of Hematology|September 2, 2011
Novel therapies in MM: from the aspect of preclinical studiesTeru Hideshima, Kenneth C Anderson
Blood|October 9, 2004
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implicationsKlaus Podar, Kenneth C Anderson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2006
Synopsis of a roundtable on validating novel therapeutics for multiple myelomaWilliam Dalton, Kenneth C Anderson
International Journal of Hematology|March 12, 2013
Histone deacetylase inhibitors in the treatment for multiple myelomaTeru Hideshima, Kenneth C Anderson
Pageof 87

Showing results (41-50 of 868) with videos related to

Sort By:
Pageof 87
CA: a Cancer Journal for Clinicians|October 1, 2014
Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and backGiada Bianchi, Kenneth C Anderson
Haematologica|October 15, 2020
Multiple myeloma: the (r)evolution of current therapy and a glance into futureAnnamaria Gulla, Kenneth C Anderson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 7, 2006
Velcade and vitamin C: too much of a good thing?Laurence Catley, Kenneth C Anderson
Expert Opinion on Drug Safety|February 27, 2020
The safety of current and emerging therapies for multiple myelomaOmar Nadeem, Kenneth C Anderson
Oncology (Williston Park, N.Y.)|June 7, 2005
Treatment options for older myeloma patients. From the Multiple Myeloma Research FoundationKenneth C Anderson, Antonio Palumbo,
BMC Biology|November 1, 2011
Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130CasDharminder Chauhan, Kenneth C Anderson
International Journal of Hematology|September 2, 2011
Novel therapies in MM: from the aspect of preclinical studiesTeru Hideshima, Kenneth C Anderson
Blood|October 9, 2004
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implicationsKlaus Podar, Kenneth C Anderson
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 24, 2006
Synopsis of a roundtable on validating novel therapeutics for multiple myelomaWilliam Dalton, Kenneth C Anderson
International Journal of Hematology|March 12, 2013
Histone deacetylase inhibitors in the treatment for multiple myelomaTeru Hideshima, Kenneth C Anderson
Pageof 87